FITC-Labeled Human CD30 / TNFRSF8 Protein, His Tag

Customer Reviews
Cat. No. / Size
Price
Qty
CD0-HF2H4-25ug
$330.00
CD0-HF2H4-200ug
$2245.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    TNFRSF8, CD30, D1S166E, Ki-1

  • Source

    FITC-Labeled Human CD30, His Tag (CD0-HF2H4) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2). It is the FITC labeled form of Human CD30, His Tag (Cat. No. CD0-H52H5).

    Predicted N-terminus: Phe 19

    Request for sequence
  • Molecular Characterization

    CD30 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 40.4 kDa. The protein migrates as 60-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling

    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

  • Protein Ratio

    The FITC to protein molar ratio is 2.5-4.5.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    CD30 SDS-PAGE

    FITC-Labeled Human CD30, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

  • Bioactivity-ELISA

     CD30 ELISA

    Immobilized Monoclonal Anti-Human CD30 Human Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human CD30, His Tag (Cat. No. CD0-HF2H4) with a linear range of 10-313 ng/mL (QC tested).

    Protocol
  • Bioactivity-FACS

     CD30 FACS

    2e5 of anti-CD30 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human CD30, His Tag (Cat. No.CD0-HF2H4) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

    Protocol

Customer Reviews
Writing Reviews

  • R*** 2021-09-22
    Likes
    Our research group work with CAR-T therapy for the treatment of hematological malignancies, and use the Fitc-Labeled Human CD30 protein for detection of CAR30 cells in patients by flow cytometry. Our results are fantastic, because the observe consistency and a reproducible experiments by flow cytometry. The logistic speed is very effective and allows us to work always up to date with our projects.

Background

Human CD30 is also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. TNFRSF-8 is expressed by activated, but not by resting, T and B cells. Also, CD30 is expressed on classical Hodgkin Lymphoma cells together with CD15. CD30 is the receptor for TNFSF8/CD30L. CD30 can interact with TRAF2 and TRAF5, and mediate the signal transduction that leads to the activation of NF-kappa-B. TNFRSF8 may play a role in the regulation of cellular growth and transformation of activated lymphoblasts. TNFRSF8 is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.

Recent Advances

 
Drug Development Progress
  • English Name:

    Tumor necrosis factor receptor superfamily member 8

  • Category:

  • Approved Drugs:

    1 Details

  • Drugs in Clinical Trials:

    22 Details

  • Highest Development Stage:

    Approved

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background